Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 3/20 | 0.42 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.39 |
| ▸ | CLK1 | P49759 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 3/20 | 0.37 |
| ▸ | KIT | P10721 | 2/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.37 |
| ▸ | MET | P08581 | 2/20 | 0.37 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL175669 | 0.87 | PIK3CA (0.42) | PIK3CANPBWR1AURKBDYRK1ACLK1 | |
| SCHEMBL174762 | 0.87 | PIK3CA (0.42) | PIK3CANPBWR1AURKBDYRK1ACLK1 | |
| SCHEMBL166643 | 0.79 | AURKA (0.48) | AURKBAURKAGSK3B | |
| SCHEMBL164991 | 0.77 | GRM2 (0.41) | GRM2 | |
| SCHEMBL176103 | 0.74 | MEN1 (0.33) | — | |
| SCHEMBL163749 | 0.74 | KDM4E (0.44) | AURKBGRM2 | |
| Hydrochloric Acid SCHEMBL28094499 | 0.73 | KDM4E (0.43) | AURKBGRM2 | |
| SCHEMBL164199 | 0.71 | CCNE2 (0.41) | GRM2 | |
| SCHEMBL174746 | 0.71 | HTR2C (0.44) | — | |
| SCHEMBL164859 | 0.71 | ADORA3 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130225578-A1 | 7-CYCLYLQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-08-29 | — | — | US | disclosed |
| EP-2611448-A1 | 7-CYCLYLQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012030912-A1 | 7-CYCLYLQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225578-A1 | 7-CYCLYLQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | JAK2, JAK3, TYK2 | PIK3CA 436/4885NPBWR1 3934/4885AURKB 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.